|
Synonyms: JJP-1212 | JJP1212
Compound class:
Antibody
Comment: Nebaprubart (JJP-1212) is a potential first-in-class monoclonal antibody that targets Fc alpha receptor (FCAR; CD89).
Peptide sequence matches for the heavy and light chains of nebaprubart are claimed in patent US20230242646 [1]. In this patent, the most likely candidate to be nebaprubart is clone 10E7 humanized VL3 (VH3SQVL3). Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Nebaprubart (JJP-1212) was progressed as a clinical candidate for the treatment of IgA‑mediated conditions, including autoimmune and fibrotic diseases. See EU clinical trial 2023-508661-33-00. The EMA granted orphan medicinal product designation in October 2022, to treat linear IgA disease. |